GT Biopharma, Inc. (GTBP)

Nasdaq: GTBP

Immunotherapy for the Treatment of Cancer

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors.

View Product Pipeline

September 2026 Interview with Michael Breen, Executive Chairman and CEO of GT Biopharma, and Dr. Jeffrey Miller, MD, Consulting Senior Medical Director

August 2026 GT Biopharma Video

May 2026 Interview with Michael Breen, Executive Chairman and CEO of GT Biopharma

March 2026 Interview with Michael Breen, Executive Chairman and CEO of GT Biopharma

January 2026 Interview with Michael Breen, Executive Chairman and CEO of GT Biopharma

About

GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE^®) technology. TriKE^® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.

Latest News

GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting
Oct 26, 2026 • 8:00 EDT | Read More

GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma
Sep 15, 2026 • 9:15 EDT | Read More

Investors

GT Biopharma, Inc. Nasdaq: GTBP

Change

Volume

52 Week Range

View Our Investor Relations